Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 9/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.63 |
| ▸ | ACE2 | Q9BYF1 | 6/20 | 0.62 |
| ▸ | CTSG | P08311 | 1/20 | 0.58 |
| ▸ | F10 | P00742 | 1/20 | 0.54 |
| ▸ | F11 | P03951 | 1/20 | 0.54 |
| ▸ | KLK1 | P06870 | 1/20 | 0.54 |
| ▸ | KLK2 | P20151 | 1/20 | 0.54 |
| ▸ | KLK14 | Q9P0G3 | 1/20 | 0.54 |
| ▸ | KLK13 | Q9UKR3 | 1/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.54 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26935074 | 0.72 | KLK5 (0.56) | KLKB1F11KLK5 | |
| SCHEMBL24218646 | 0.69 | ITGB3 (0.58) | KLKB1F10F11KLK1KLK2 | |
| SCHEMBL26935045 | 0.69 | KRAS (0.58) | KLKB1EPHA2KLK5 | |
| SCHEMBL24725084 | 0.69 | ELANE (0.57) | KLKB1ACE2PLAU | |
| SCHEMBL24218675 | 0.68 | KLKB1 (0.59) | KLKB1CTSGPLAU | |
| SCHEMBL24691536 | 0.68 | KLK5 (0.72) | KLKB1F11KLK5 | |
| SCHEMBL26935056 | 0.68 | ITGB3 (0.61) | KLKB1KLK5 | |
| SCHEMBL24218595 | 0.68 | KLKB1 (0.59) | KLKB1CTSGPLAU | |
| SCHEMBL24218598 | 0.68 | KLKB1 (0.59) | KLKB1CTSGPLAU | |
| Cyclonellin SCHEMBL31094306 | 0.68 | SLC6A3 (0.53) | KLKB1KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | BICYCLETX LIMITED (GB) | 2021-02-16 | — | — | US | disclosed |
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | BICYCLETX LIMITED (GB) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131228-A1 | BICYCLIC PEPTIDE LIGANDS AND USES THEREOF | VIP, NGLY1, BID | KLKB1 322/4885EPHA2 364/4885ACE2 960/4885 |
| US-10919937-B2 | Bicyclic peptide ligands and uses thereof | VIP, NGLY1, BID | KLKB1 322/4885EPHA2 364/4885ACE2 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.